Linda has been living with stage IV lobular breast cancer — cancer that has spread beyond the breast — since her diagnosis in 2021, a little over five years. She receives her care from Dr. Jason Mouabbi, a breast medical oncologist at The University of Texas MD Anderson Cancer Center.
With stage IV breast cancer, a key question is how well treatment is working. For Linda, scans alone could not answer that question. Lobular breast cancer can grow and spread in a pattern that is difficult to see or measure on imaging, and in Linda’s case, Dr. Mouabbi explains, imaging could not show her cancer at all. To tell whether her treatment was working, her care team added circulating tumor DNA, or ctDNA, testing — a blood test she now has about every three months.
- Linda’s experience living with stage IV lobular breast cancer
- Why lobular breast cancer can be difficult to see on scans
- How ctDNA testing works — and why it is matched to each person’s tumor
- What rising, falling, or cleared ctDNA levels can suggest about treatment
- How a sharp rise in Linda’s results signaled that it was time to change treatment
- Why small fluctuations in results matter less than big changes
- What studies show about ctDNA levels during treatment for metastatic breast cancer
- Linda’s perspective on what testing is like and the reassurance it provides
Circulating tumor DNA, or ctDNA, is DNA from cancer cells that can sometimes be found in the bloodstream. As cells break down, they can release DNA into the blood.
Dr. Mouabbi explains that ctDNA testing is often “tumor-informed.” Information from a prior surgery or biopsy is used to identify mutations that are unique to a person’s tumor and not present in healthy cells. The blood test then looks for DNA carrying those specific mutations — because if that DNA is found in the blood, it can only be coming from the cancer.
In the metastatic setting, this test can be especially useful in cancers that are poorly visualized on scans, such as lobular breast cancer. The amount of cancer DNA in the blood tends to correlate with how active the cancer is: when the level stays the same or goes down, it suggests treatment is controlling the disease; when the level is going up, it suggests the disease is becoming more active and the treatment is no longer controlling it.
A ctDNA result does not determine treatment on its own. It is one input that is interpreted together with imaging, symptoms, physical exams, treatment history, and the full clinical picture.
For hormone-driven metastatic breast cancer, anti-hormonal therapy is often the backbone of treatment. But over time, the cancer can stop depending on hormones — something Dr. Mouabbi says is very important to catch as soon as possible.
In Linda’s case, a sharp rise in her ctDNA told her care team that her hormonal treatment was no longer working. Her team switched her to a non-hormonal therapy delivered by IV. When the test was repeated about two months later, her ctDNA had dropped close to zero — a large decline that was very reassuring to both Linda and her care team that the new treatment was working.
Dr. Mouabbi also cautions that small changes in ctDNA results are usually not a reason to react. ctDNA is short-lived in the bloodstream, so results naturally fluctuate from test to test. What matters are big changes — such as a doubling or tripling of levels — which are more likely to warrant a closer look.
Across many studies in metastatic breast cancer and other cancers, a decrease in ctDNA — or a clearance, meaning the level becomes undetectable — while on therapy has been shown to track with more favorable outcomes. Researchers continue to study how these results should best be used to guide treatment decisions.
ctDNA monitoring during treatment is not yet standard care for everyone with metastatic breast cancer, and it is different from tests that look for gene changes to help match a treatment to a tumor. Whether and how to use it is an individual decision made with the care team.
Questions to ask your care team
If you are living with metastatic breast cancer, you may want to ask:
- How will we know whether my treatment is working?
- Is ctDNA testing appropriate for my type and stage of breast cancer?
- Is this test looking for gene changes to help match treatment, tracking ctDNA levels over time, or both?
- What would a rising or falling ctDNA result mean for my care?
- How often would I have testing, and how soon would results be available?
- If my ctDNA changes, what else would we consider before changing treatment?
- Is ctDNA testing covered by my insurance, and are financial-assistance options available?
- Are there clinical trials evaluating ctDNA-guided monitoring or treatment in metastatic breast cancer that may be appropriate for me?
Linda describes her testing experience as “wonderful” and says it has helped her treatment. Her story underscores the value of an individualized monitoring plan for metastatic breast cancer. As Dr. Mouabbi notes, ctDNA testing is widely available — patients can ask their oncologist about it, learn what their team knows about it, and make an informed, shared decision about whether it is appropriate for them.
Patient information disclaimer
Linda’s experience is personal and may not represent the experience of every person with metastatic breast cancer. ctDNA testing is not appropriate for every patient and does not replace imaging, laboratory testing, physical examination, clinical follow-up, or individualized guidance from an oncology care team. Monitoring during treatment for stage IV breast cancer is different from follow-up surveillance after treatment for early-stage breast cancer. Patients should discuss their diagnosis, treatment history, and monitoring options with their doctor.
This educational resource was made possible by Natera, OmniOncology, and The Personalized Medicine Foundation.
More in this series
- Ken’s Story: Understanding ctDNA After Colorectal Cancer Surgery
- Ken’s Story: Using ctDNA to Help Navigate Colorectal Cancer Follow-Up
- Mary Jo’s Story: ctDNA Monitoring, MSI-High Colorectal Cancer, and Immunotherapy
- Shawn’s Story: ctDNA Monitoring After Treatment for Muscle-Invasive Bladder Cancer
- Lynda’s Story: ctDNA Monitoring After Treatment for Stage III Lobular Breast Cancer





